OVERVIEW

Community Practice Connections™: The Latest Advances on PI3K Inhibition in Breast Cancer: What You Need to Know is organized by Physicians' Education Resource, LLC (PER).

Release Date: Nov 15, 2019
Expiration Date: Nov 15, 2020

Target Audience:
This educational activity is directed toward community oncologists and hematologists who treat patients with breast cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate.

Accreditation/Credit Designation:
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

PER® estimates that this online enduring material will be designated for a maximum of 1.0 credit for nurses.

Activity Overview:
This educational activity will bring together leading clinical experts in the management of patients with breast cancer using phosphoinositide 3-kinase (PI3K) inhibitors. The in-depth program will cover best practices for identification of patients with breast cancer who are most likely to benefit from these agents, the specific mechanistic characteristics of available agents, and techniques for managing adverse events appropriately. In addition, available clinical trial data will be examined and contextualized in patient cases, including trials of emerging strategies utilizing combination approaches incorporating PI3K inhibition. The program will include a focused discussion on optimizing the use of PI3K inhibitors using the most advanced and most accurate available tumor-testing technologies.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Discuss that rationale supporting the role of PI3K inhibition in the treatment of patients with breast cancer
• Review data from recent clinical trials evaluating efficacy and safety of PI3K inhibitors in breast cancer treatment
• Examine strategies for optimizing treatment outcomes and patient selection for PI3K inhibition
• Discuss effective strategies to proactively counsel and manage adverse events associated with PI3K inhibition in the treatment of patients with breast cancer

Additional details will be posted as soon as information is available.